Prior outpatient antibacterial therapy as prognostic factor for mortality in hospitalized pneumonia patients  by van de Garde, Ewoudt M.W. et al.
ARTICLE IN PRESSRespiratory Medicine (2006) 100, 1342–13480954-6111/$ - s
doi:10.1016/j.r
Abbreviation
chronic disease
Correspond
Sorbonnelaan 1
E-mail addrPrior outpatient antibacterial therapy as prognostic
factor for mortality in hospitalized pneumonia
patients
Ewoudt M.W. van de Gardea,b,, Patrick C. Souvereina,
Jules M.M. van den Boschc, Vera H.M. Deneerb, Wim G. Goettschd,
Hubert G.M. LeufkensaaDepartment of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical
Sciences, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
bDepartment of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands
cDepartment of Pulmonary Diseases, St. Antonius Hospital, Nieuwegein, The Netherlands
dPHARMO Institute, Utrecht, The Netherlands
Received 1 August 2005; accepted 28 November 2005KEYWORDS
Antibacterial agents;
Heart failure;
Mortality;
Pneumoniaee front matter & 2005
med.2005.11.024
s: CAP, community-acq
score; ICD, Internation
ing author. Department
6, 3584 CA Utrecht, Th
ess: e.m.w.vandegardeSummary
Study objectives: To assess whether prior outpatient treatment is associated with
outcome in patients hospitalized for community-acquired pneumonia (CAP).
Patients and methods: All patients with a first hospital admission for CAP between
1995 and 2000 were selected. Patients were divided into two groups, one of patients
with use of antibacterial agents prior to hospitalization and one of patients treated
as inpatient directly. The main outcome measures were duration of hospital stay and
in-hospital mortality.
Results: The two patient groups comprised 296 and 794 patients, respectively. The
median duration of hospital stay was 10 days and was similar for both groups. In
patients with respiratory diseases or heart failure, the median duration of hospital
stay was 12 and 14 days, respectively. The overall in-hospital mortality was 7.2% and
did not largely differ between both groups. In patients with congestive heart failure,
the mortality was 9.8% for controls and 23.3% for patients hospitalized after initial
outpatient treatment (adjusted OR 2.78, 95% CI 1.01–7.81).Elsevier Ltd. All rights reserved.
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Outpatient antibacterial therapy and mortality 1343Conclusions: Prior outpatient antibacterial therapy is not associated with outcome
in hospitalized pneumonia patients. In patients with underlying chronic heart
failure, prior outpatient antibiotic is associated with a significant increased
mortality.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Community-acquired pneumonia (CAP) is a major
direct cause of death in the elderly with mortality
rates for inpatients varying from 5% to 20%.1,2
Approximately 20% of all patients with pneumonia
require inpatient treatment.3,4 Whether to treat a
patient with CAP as an outpatient or as an inpatient
is an extremely important decision. Nowadays
many guidelines give directions for making this
decision.5–9 Despite these guidelines still patients
fail initial outpatient treatment and get hospita-
lized subsequently. To our knowledge hardly any
studies about factors influencing outcome in hospi-
talized pneumonia patients include failure of initial
outpatient antibacterial drug treatment as prog-
nostic factor. Considering that the clinical course of
patients with CAP within the first 2–3 days is crucial
in relation to disease outcome,10 it seems logical to
suspect that patients who fail initial outpatient
antibacterial therapy and get subsequently hospi-
talized could be at increased risk for worse
outcome compared with patients treated as an
inpatient directly. The objective of this study was
to assess whether prior outpatient antibacterial
therapy is associated with outcome in patients
hospitalized for CAP.Patients and methods
Data setting
The setting of the study was the PHARMO record
linkage system (www.pharmo.nl). PHARMO includes
pharmacy dispensing records from community
pharmacies linked to hospital discharge records of
more than 600,000 community-dwelling residents
of more than eight population-defined areas in the
Netherlands from 1985 onwards.11 Since virtually
all patients in the Netherlands are registered with a
single community pharmacy independently of pre-
scriber, pharmacy records are virtually complete
with regard to prescription drugs.
The computerized drug dispensing histories con-
tain information concerning the dispensed drug,
dispensing date, the prescriber, amount dispensed,prescribed dosage regimen, and the estimated
duration of use. The duration of use of each
dispensed drug is estimated by dividing the number
of dispensed units by the prescribed number of
units to be used per day. Drugs are coded according
to the Anatomical Therapeutic Chemical (ATC)
classification. The hospital discharge records are
obtained from PRISMANT (www.prismant.nl), pre-
viously known as the Dutch Center for Healthcare
Information (LMR database), an institute that
collates nationwide all hospital discharge records
in the Netherlands since the 1960s into a standar-
dized format. These records include detailed
information concerning the primary and secondary
discharge diagnoses, diagnostic, surgical and treat-
ment procedures, type and frequency of consulta-
tions with medical specialists and dates of hospital
admission and discharge. All diagnoses are coded
according to the International Classification of
Diseases, 9th edition (ICD-9).
Study base
The study base comprised all patients with a first
hospital admission for CAP between January 1,
1995, and December 31, 2000. All patients were
selected according to the following criteria: adult
(418 years old) and hospitalized with a primary
discharge diagnosis of CAP: pneumococcal pneu-
monia (ICD-9 code 481), other bacterial pneumonia
(ICD-9 code 482), bronchopneumonia, organism
unspecified (ICD-9 code 485) or pneumonia, organ-
ism unspecified (ICD-9 code 486). Besides this,
patients with a signature of bacterial pneumonia
(secondary discharge diagnosis) coupled with a
primary pulmonary diagnosis (ICD-9 codes 491–493
or 496) were selected. For all subjects, pharmacy
dispensing data were collected. Patients were
eligible if they had at least 365 days of exposure
information prior to hospital admission available in
the PHARMO record linkage system.
Definition of groups
For each patient, we identified all prescriptions for
antibacterial agents (ATC code J01A to J01X) within
the year prior to the date of hospital admission.
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bacterial drug use for pneumonia varies from 7 to
10 days.12–14 Patients were divided into two groups.
Patients hospitalized without a prescription for an
antibacterial drug within 2 weeks prior to the
hospital admission date were considered inpatient
treatment only. All patients who received one or
more antibacterial drugs within the 2 weeks prior
to hospitalization were considered as hospitalized
after prior outpatient treatment. For these pa-
tients the duration of outpatient antibacterial drug
use was calculated as the number of days between
dispensing and hospital admission. Based on dura-
tion of use, patients with prior antibiotic use were
further subdivided in early failure (duration of
usep3 days) and late failure (duration of use43
days). Antibiotics prescribed were classified as
appropriate when mentioned in the reigning Dutch
guidelines for initial treatment of pneumonia.12–14
Outcome measures
The duration of hospital stay was defined as the
difference between the admission and discharge
date. If the date of death in the PHARMO record
linkage system was similar to the hospital discharge
date, the patient was considered to have died in
the hospital.
Co-morbidity assessment
Besides antibacterial agents also cardiovascular
medication, respiratory drugs, immunosuppressive
agents, cancer medication and flu vaccination were
identified to address co-morbidities related with
outcome in CAP.1,2,15,16 When a patient received
bronchodilators and or inhaled corticosteroids, the
patient was considered as suffering from respira-
tory diseases. The combination of a diuretic with a
cardiac glycoside was considered as signature for
congestive heart failure (CHF). For these groups of
drugs one was considered exposed if more than one
dispensing occurred in the 12-month period prior to
hospitalization, except for flu vaccination, which
required just one dispensing. To evaluate the
overall health status of the patients, for each
patient the Chronic Disease Score (CDS) was
calculated based on patterns of use of selected
prescription medications during a 1-year period
identified by a consensus judgment process.17
Data analysis
Mann–Whitney U-tests were used to compare
duration of hospital stay between groups. Logisticregression analysis was used to calculated crude
and adjusted odds ratios (OR) and 95% confidence
intervals (CI) (SPSS for Windows, version 11.0;
SPSS Inc., Chicago, Illinois, USA).Results
The study population comprised 1090 patients with
a first hospital admission for CAP. We identified 296
patients with prior antibiotic use (27% of all CAP
admissions) and 794 patients hospitalized with no
prior antibiotic use. Table 1 shows the character-
istics of both groups. The overall mean age was 67
years (70.7 years) and was not different between
both groups. Also, the CDSs were comparable,
indicating that the overall health status did not
differ between both groups. In our study population
almost 97% of all patients had a primary diagnosis
of CAP, and most of them had a pneumonia with
unspecified organism (about 72%) recorded in the
hospital abstract. Table 2 lists all the antibiotics
prescribed for the prior antibiotic group within the
2 weeks prior to hospitalization. Figure 1 shows the
duration of outpatient antibacterial drug use
before hospitalization. Based on this, 126 patients
were classified as ‘‘early failure’’ and 170 patients
as ‘‘late failure’’. More than 92% of the antibiotics
prescribed was appropriate according to the reign-
ing Dutch guidelines for the initial treatment of
CAP.12–14 Almost 90% of all prescriptions originated
from a general practitioner. The overall median
duration of hospital stay was 10 days and similar for
both groups (10 vs. 10 days, respectively) and did
not show a significant difference (P ¼ 0:787). For
‘‘late failure’’ patients, the median duration of
hospital stay was 11 days. In patients with
respiratory diseases and CHF, the median duration
of hospital stay was significantly higher (12 and 14
days, respectively; Po0:01).
From all patients, 79 deceased in hospital. This
gives an overall in-hospital mortality of 7.2%. All
patients who died during their hospital admission
were compared with patients who left the hospital
alive with respect to prior antibiotic use, age,
respiratory diseases, immunosuppressive therapy,
CHF and flu vaccination (Table 3). Age was
significantly associated with an increased risk of
in-hospital mortality (adjusted OR 1.37, 95% CI
1.14–1.66). Overall, prior antibiotic use was not
associated with in-hospital mortality (adjusted OR
1.09, 95% CI 0.65–1.83). Furthermore, no differ-
ences were observed between ‘‘early failure’’ and
‘‘late failure’’. Considering different co-morbid-
ities, patients with CHF showed a higher in-hospital
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Table 1 Characteristics of both groups.
Characteristic Prior outpatient
treatment (n ¼ 296)
Inpatient treatment
only (n ¼ 794)
Crude OR (95% CI)
Age (years)
o40 33 (11.1) 64 (8.1)
40–49 22 (7.4) 68 (8.6)
50–59 23 (7.8) 92 (11.6)
60–69 55 (18.6) 133 (16.8)
70–79 92 (31.1) 260 (32.7)
80–89 62 (20.9) 152 (19.1)
X90 9 (3.0) 25 (3.1)
Gender
Male 169 (57.1) 466 (58.7) 1.00 (reference)
Female 127 (42.9) 328 (41.3) 1.07 (0.82–1.40)
Primary discharge diagnosis
Pneumococcal pneumonia 12 (4.1) 69 (8.7)
Other bacterial pneumonia 21 (7.1) 62 (7.9)
Bronchopneumonia, organism
unspecified
37 (12.5) 100 (12.6)
Pneumonia, organism unspecified 219 (74.0) 536 (67.5)
Chronic disease score
0 58 (19.6) 162 (20.4) 1.00 (reference)
1–3 55 (18.6) 152 (19.1) 1.01 (0.66–1.55)
4–6 67 (22.6) 205 (25.8) 0.91 (0.61–1.37)
7–9 54 (18.2) 142 (17.9) 1.06 (0.69–1.64)
X10 62 (20.9) 133 (16.8) 1.30 (0.85–1.99)
Co-medication
Respiratory drugs 128 (43.2) 322 (40.6) 1.12 (0.85–1.46)
Cardiovascular drugs 162 (54.7) 466 (58.7) 0.85 (0.65–1.11)
Flu vaccination 58 (19.6) 180 (22.7) 0.83 (0.60–1.16)
In-hospital mortality 24 (8.1) 55 (6.9) 1.19 (0.72–1.95)
OR: odds ratio; CI: confidence interval.
Outpatient antibacterial therapy and mortality 1345mortality (adjusted OR 1.83, 95% CI 1.01–3.32).
Patients with heart failure and failure of prior
outpatient treatment had a significant higher
mortality rate (23.3%) compared with heart failure
patients treated as inpatient directly (mortality
rate: 9.8%; adjusted OR 2.78, 95% CI 1.01–7.81).
Respiratory disease was not associated with in-
creased mortality in CAP (adjusted OR 0.92, 95% CI
0.54–1.55).Discussion
In this study, prior outpatient antibiotic treatment
was not associated with outcome in patients
hospitalized for pneumonia. The duration of hospi-
tal stay and in-hospital mortality rates found in this
study were comparable with other studies concern-ing hospitalized pneumonia patients.1,2 For pa-
tients with heart failure who were hospitalized
after initial outpatient therapy, the in-hospital
mortality was two-fold increased compared with
heart failure patients treated as inpatient directly.
Literature indicates that in approximately 20%
of all pneumonia cases inpatient treatment is
required because the clinical situation does not
allow outpatient treatment.2–4 The decision be-
tween outpatient and inpatient treatment will in
most cases be made by the general practitioner.
This notion has been confirmed by the present
study with almost 90% of the prescriptions for
antibacterial drugs originating from a general
practitioner. Still many patients, however, fail the
initial outpatient antibacterial treatment and get
subsequently hospitalized. In the present study,
almost 30% of the patients was hospitalized after
initial outpatient treatment. Although mortality
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Table 2 Outpatient antibiotics utilization profile prior to hospitalization for community-acquired pneumonia.
Type of antibacterial drug ATC-code No. of users (%) Appropriate
Amoxicillin/clavulic acid J01CR02 74 (22.0) Yes
Amoxicillin J01CA04 73 (21.7) Yes
Doxycyclin J01AA02 53 (15.7) Yes
Clarithromycin J01FA01 35 (10.4) Yes
Ofloxacin J01MA01 18 (5.3) No
Co-trimoxazol J01EE01 17 (5.0) Yes
Azythromycin J01FA10 16 (4.7) Yes
Roxithromycin J01FA06 11 (3.3) Yes
Ciprofloxacin J01MA02 10 (3.0) No
Erythromycin J01FA01 9 (2.7) Yes
Cephalosporin J01DA 3 (0.9) Yes
Norfloxacin J01MA06 3 (0.9) No
Trimethoprim J01EA01 3 (0.9) No
Flucloxacilin J01CF05 2 (0.6) No
Aminoglycosides J01G 1 (0.3) No
Other antibacterials J01X 9 (2.7) Unknown
Based on reigning Dutch guidelines NVALT, SWAB and NHG (12–14).
Duration of use (days)
>1413121110987654321
N
um
be
r o
f c
as
es
60
50
40
30
20
10
0
Figure 1 Duration of outpatient antibacterial drug use
before hospitalization.
E.M.W. van de Garde et al.1346seemed a little higher for these patients compared
with patients treated as inpatient directly (8.1% vs.
6.9%, respectively), no significant association could
be observed between initial outpatient treatment
and mortality in patients hospitalized for pneumo-
nia. Our study had sufficient power to detect a two-
fold difference in mortality rates between the two
groups (a ¼ 0:05; ð1 bÞ ¼ 0:80). When considering
literature on this subject, there is the recent study
of Marrie et al. which showed an indicative
increased in-hospital mortality of 11.3% for pa-
tients with former outpatient antibacterial therapy
compared with patients hospitalized without, i.e.
8.2%.15 In contrast, however, Johnson et al.
associated antibiotic utilization prior to hospitali-zation for pneumonia with a decreased in-hospital
mortality,18 something which could not be con-
firmed by the present study.
When considering different types of patients, we
found that heart failure was associated with an
increased in-hospital mortality (adjusted OR 1.83,
95% CI 1.01–3.32). This finding complies with
literature addressing CHF as risk factor for worse
outcome in CAP.1,2,15,16,19 Most interestingly, our
study indicated that heart failure patients hospita-
lized after prior outpatient antibacterial therapy
had an even higher mortality compared with heart
failure patients treated as inpatient directly (23.3%
vs. 9.8%). One possible explanation for the ob-
served higher mortality in these patients could be
that they received inappropriate outpatient anti-
bacterial therapy.18 However, more than 90% of the
antibiotics prescribed were appropriate according
to the reigning Dutch guidelines for initial anti-
bacterial therapy in pneumonia. Additionally, the
percentage of appropriate antibacterial therapy
did not differ between patients who died and
patients who left the hospital alive. A more obvious
explanation for the observed higher mortality for
the cases with heart failure might be related to the
fact that patients with a combination of pneumonia
and heart failure are more susceptible for dete-
rioration of the clinical situation and with this that
initial outpatient treatment would delay the
hospital treatment which is essential to rescue this
type of severe patients. This may actually indicate
that general practitioners underestimate the
severity and impact of pneumonia in these pa-
tients, leading to an increased mortality in hospital
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Table 3 Odds ratios (OR) for in-hospital mortality and the use of outpatient antibacterial therapy, co-morbidity
and other drug treatment.
Dead (n ¼ 79) Alive (n ¼ 1011) Crude OR (95% CI) Adjusted OR (95% CI)
Outpatient therapy 24 (30.4) 272 (26.9) 1.19 (0.72–1.95) 1.09 (0.65–1.83)
Without CHF 14 (17.7) 239 (23.6) 0.85 (0.44–1.62) 0.87 (0.45–1.68)
With CHF 10 (12.7) 33 (3.3) 2.96 (1.07–8.23) 2.78 (1.01–7.81)
Early failure 6 (7.6) 120 (11.9) 0.60 (0.26–1.43) 0.61 (0.26–1.45)
Late failure 18 (22.8) 152 (15.0) 1.92 (1.06–3.48) 1.53 (0.87–2.71)
Respiratory diseases 37 (46.8) 413 (40.9) 1.28 (0.81–2.02) 0.92 (0.54–1.55)
CHF 59 (74.7) 569 (56.3) 2.49 (1.42–4.38) 1.83 (1.01–3.32)
Flu vaccination 19 (24.1) 219 (21.7) 1.15 (0.67–1.96) 0.93 (0.53–1.62)
Cancer medication 4 (5.7) 47 (4.6) 1.09 (0.38–3.12) 1.13 (0.38–3.33)
Immunosuppressive 18 (22.8) 155 (15.3) 1.63 (0.94–2.83) 1.40 (0.75–2.58)
Adjusted for age, gender, respiratory diseases, flu vaccination, immunosuppressive, cancer medication; OR: odds ratio; CHF:
congestive heart failure.
Outpatient antibacterial therapy and mortality 1347when outpatient therapy fails. Although the Pneu-
monia Severity of Illness score and AMBU-65
scores20,21 use heart failure to predict outcome it
may be suggested to directly admit all pneumonia
patients with underlying chronic heart failure to
the hospital in order to decrease mortality.
Strength of our database study in comparison to
other studies about factors influencing in-hospital
mortality in CAP is that we had the possibility to
study a large number of patients. But our study also
had some limitations. One limitation is that we
included pneumonia based on ICD-9 codes.22 In our
study, over 70% of the patients had a diagnosis of
pneumonia of unspecified organism recorded. It is
known from literature that the etiology of the
infectious agent in many pneumonia cases remains
unknown.23 This could imply that, for example,
some nonpneumonic exacerbations of COPD could
be incorrectly recorded as pneumonia. But other
studies using advanced analytical techniques report
percentages with known etiology up to 87%,24,25
indicating that the fact no organism was specified
using conventional techniques does not imply no
pathogen was involved. An additional limitation is
that we had no information about the exact clinical
situation at the time of hospitalization, so both
groups may not be entirely comparable. The CDS
scores, however, showed no differences between
both groups. Another limitation is the definition of
heart failure used in this study. We realize that the
use of a diuretic in combination with a cardiac
glycoside as marker for heart failure can be
debated and that it is difficult to assess the exact
severity of CHF based on drug prescriptions and we
can therefore not further distinguish between
different classes of these patients. However, pre-
vious studies have shown that the use of this
marker is in general adequate.26–28In summary, our study confirms that many
pneumonia patients are hospitalized after prior
outpatient treatment. Although the overall dura-
tion of hospital stay and in-hospital mortality are
not significantly increased after failure of out-
patient therapy, we conclude that patients with
CHF are at increased risk for worse outcome when
outpatient therapy of CAP fails and they get
hospitalized subsequently. Based on these findings,
we suggest that patients with CHF should be
carefully monitored when treated as outpatient or
treated as inpatient directly when presenting with
symptoms of pneumonia.Disclosure
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